Related Experiment Video
Updated: Mar 19, 2026

Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections
Published on: November 8, 2024
Apolipoprotein E isotype-dependent modulation of microRNA-146a in plasma and brain
Bruce Teter1, Mary Jo LaDu, Patrick M Sullivan
1aGeriatric Research Education and Clinical Center, Veterans Greater Los Angeles Healthcare System bDepartments of Neurology and Medicine, University of California, Los Angeles, California cDepartment of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, Illinois dGRECC, Durham Veterans Affairs Medical Center eDepartment of Medicine (Geriatrics), Duke University Medical Center, Durham, North Carolina.
Abstract:
The Apolipoprotein E (ApoE) isotype ApoE4 is a prevalent genetic risk factor for Alzheimer's disease (AD) that can modulate systemic and central inflammation, independent of amyloid accumulation. Although disruption of innate immune toll receptor signaling is modulated by ApoE and observed in AD, ApoE isotype-specific effects remain poorly understood. Therefore, we examined the effect of the ApoE isotype on the brain levels of major regulators of TLR signaling including miR146a, a microRNA enriched in the brain. We used 6-month-old ApoE3 or ApoE4 targeted replacement mice with and without mutant familial AD transgenes. ApoE4 reduced the levels of miR146a compared with ApoE3, both in the brain (29%; P<0.0001) and in plasma (47%; P<0.05), which correlated with each other (r=0.74; P<0.05). The presence of 5xFAD transgenes increased brain miR146a in both ApoE3 (E3FAD) and ApoE4 (E4FAD) mice; however, miR146a levels in E4FAD mice remained lower than those in E3FAD mice (62%; P<0.05), despite increased amyloid and inflammation. Supporting these observations, ApoE4 brains showed increased expression of interleukin receptor-associated kinase-1 (160%; P<0.05) (normally downregulated by miR146) that correlated inversely with miR146a levels (r=0.637; P<0.0001). Reduced negative feedback of toll-like receptor signaling (by miRNA146a) can explain early-life hypersensitivity to innate immune stimuli (including Aβ) in ApoE4 carriers. Thus, ApoE4 causes early dysregulation of a central controller of the innate immune system both centrally and systemically. This defect persists with familial AD pathology and may be relevant to ApoE4 AD risk.
Insights
Apolipoprotein E4 (ApoE4) reduces miR146a levels, a key regulator of innate immunity, in the brain and plasma. This early dysregulation in ApoE4 carriers may explain increased Alzheimer's disease risk.
Area of Science:
- Neuroimmunology
- Genetics of Alzheimer's Disease
- Molecular Biology
Background:
- Apolipoprotein E4 (ApoE4) is a major genetic risk factor for Alzheimer's disease (AD).
- Innate immune toll receptor signaling is disrupted in AD, but ApoE isotype-specific effects are unclear.
- MicroRNA-146a (miR146a) is a key regulator of toll-like receptor (TLR) signaling, particularly in the brain.
Purpose of the Study:
- To investigate the impact of Apolipoprotein E (ApoE) isotype on brain and plasma levels of miR146a.
- To determine if ApoE isotype affects miR146a regulation in the context of familial Alzheimer's disease (AD) pathology.
- To explore the relationship between miR146a levels and key inflammatory markers in ApoE4 carriers.
Main Methods:
- Utilized 6-month-old targeted replacement mice expressing either ApoE3 or ApoE4.
- Included mice with and without mutant familial AD transgenes (5xFAD).
- Quantified brain and plasma miR146a levels and assessed interleukin receptor-associated kinase-1 (IRAK1) expression.
Main Results:
- ApoE4 significantly reduced miR146a levels in both brain and plasma compared to ApoE3.
- Familial AD transgenes increased miR146a, but levels remained lower in ApoE4 mice despite higher amyloid and inflammation.
- ApoE4 brains exhibited increased IRAK1 expression, inversely correlated with miR146a levels, indicating impaired negative feedback.
Conclusions:
- ApoE4 causes early, systemic dysregulation of miR146a, a central innate immune regulator.
- This defect persists in the presence of familial AD pathology and may contribute to ApoE4's role in AD risk.
- Reduced miR146a-mediated negative feedback in ApoE4 carriers could lead to hypersensitivity to innate immune stimuli, including amyloid-beta.
More Related Videos
Related Concept Videos
MicroRNAs
MicroRNAs
MicroRNAs
RNA Editing
Regulated mRNA Transport

